News & Opinion - 2021
– Health AffairsNew Medicare Technology Add-On Payment Could Be Used as a Market Support Mechanism to Accelerate Antibiotic Innovation
Despite growing antibiotic resistance, the development pipeline for antibiotics has slowed; Kevin Schulman and GSB alumni Neil Gandhi propose three approaches to encouraging funding and development.
– BMJ Global HealthNovel strategies to support global promotion of COVID-19 vaccination
In this new paper, CERC’s Kevin Schulman asserts that consumer marketing practices in the US can boost Covid-19 vaccination rates globally – if they are adapted to local cultures.
– IEEE XploreSmart Home Technologies Are Saving Money and Lives
By building "ambient intelligence" into places where at-risk individuals reside, CERC researchers are looking to improve outcomes while respecting privacy.
– New York TimesOur drug supply is sick. How can we fix it?
CERC’s Kevin Schulman: “The free market simply isn’t working for generic drugs.”
– Stanford Medicine ScopeStudy finds convalescent plasma therapy ineffective for COVID-19
New research details how this once-promising treatment disappointed.
– WSJ Opinion|CommentaryA False Narrative About ‘Misinformation’ and Covid Vaccines
In this op-ed in The Wall Street Journal, Bob Kaplan writes that vaccine hesitancy is a pre-existing condition: "The internet is awash with misinformation about the vaccines. But data distortion seems to have little effect on vaccine uptake."
– Stanford News Center5 Questions: Kevin Schulman on whether taxpayers should pay for controversial new Alzheimer’s drug
CERC’s Kevin Schulman weighs in on the likely impact of the FDA’s approval of Aduhelm.
– MedPage Today: Second OpinionIs Confirmation Bias Guiding COVID Vaccine Recommendations?
Op-Ed:Is Confirmation Bias Guiding COVID Vaccine Recommendations?